• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke

byStudy Graphics | C.WuandConstance Wu
August 22, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients presenting between 4.5 and 9 hours after stroke onset with viable brain tissue who received thrombolytic therapy had better neurological outcomes compared to those receiving placebo.

2. Symptomatic intracranial hemorrhage occurred in a higher number of patients in the thrombolysis group compared to placebo group.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Guidelines for thrombolytic therapy after ischemic stroke recommend thrombolytic use within 4.5 hours of stroke onset. Imaging with CT and MRI methods are now able to determine whether brain tissue is viable after stroke, giving rise to the possibility of determining if patients should receive thrombolytic therapy based on tissue viability in addition to time since stroke. The EXTEND trial is a phase 3 randomized controlled trial evaluating functional outcomes of patients receiving alteplase or placebo between 4.5 and 9 hours from stroke onset. At 90 days since treatment, patients who received alteplase had better neurological outcomes compared to those treated with placebo. A higher number of patients receiving alteplase experienced symptomatic intracranial hemorrhage than in the placebo group.

This study provides strong evidence for considering information about tissue viability from imaging in deciding whether to administer thrombolytic therapy for patients with delayed hospital presentation after stroke. The study’s strengths are its randomized controlled design and use of either CT or MRI for tissue viability determination. The study was limited by the smaller than planned number of patients recruited for the trial.

Click to read the study in NEJM

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

RELATED REPORTS

CYP2C19 loss-of-function carriers have modest benefit from ticagrelor and aspirin following cerebrovascular event: CHANCE-2 Trial

#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk

The EAST-AFNET 4 trial: Early rhythm control therapy for atrial fibrillation [Classics Series]

Tags: altepaseischemic strokereperfusionstrokethrombolysis
Previous Post

Quick Take: Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART)

Next Post

Quick Take: Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer

RelatedReports

Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Chronic Disease

CYP2C19 loss-of-function carriers have modest benefit from ticagrelor and aspirin following cerebrovascular event: CHANCE-2 Trial

June 23, 2022
#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk
StudyGraphics

#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk

June 16, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Cardiology Classics

The EAST-AFNET 4 trial: Early rhythm control therapy for atrial fibrillation [Classics Series]

June 13, 2022
FDA-approved weight loss medications associated with weight loss at one year
Cardiology

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

May 25, 2022
Next Post
High rates of over-diagnosis of pulmonary embolism by CT angiography

Quick Take: Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer

The EXTEND trial: neurological deficits decreased with thrombolysis up to 9 hours after stroke onset

Unrecognized myocardial infarctions associated with embolic cerebral infarctions of undetermined source

Adolescents with mental health problems at higher risk for e-cigarette use

Adolescents with mental health problems at higher risk for e-cigarette use

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.